Recent Analysts’ Ratings Updates for Masimo (MASI)

A number of research firms have changed their ratings and price targets for Masimo (NASDAQ: MASI):

• 11/6/2024 – Masimo had its price target raised by analysts at Wells Fargo & Company from $160.00 to $171.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Masimo had its price target raised by analysts at Piper Sandler from $165.00 to $180.00. They now have an “overweight” rating on the stock.
• 11/6/2024 – Masimo was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating. They now have a $170.00 price target on the stock.
• 11/6/2024 – Masimo had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/18/2024 – Masimo had its “overweight” rating reaffirmed by analysts at Piper Sandler.
• 10/14/2024 – Masimo had its price target raised by analysts at BTIG Research from $166.00 to $170.00. They now have a “buy” rating on the stock.
• 9/20/2024 – Masimo had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Masimo Stock Performance

Shares of NASDAQ MASI opened at $162.41 on Monday. Masimo Co. has a 52-week low of $81.82 and a 52-week high of $173.90. The stock has a market capitalization of $8.70 billion, a price-to-earnings ratio of 112.01 and a beta of 0.97. The company has a quick ratio of 1.15, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The stock’s fifty day simple moving average is $133.52 and its 200 day simple moving average is $125.93.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.63 earnings per share. As a group, sell-side analysts forecast that Masimo Co. will post 4.04 earnings per share for the current fiscal year.

Institutional Trading of Masimo

Large investors have recently added to or reduced their stakes in the company. Edgestream Partners L.P. acquired a new position in Masimo during the second quarter valued at $645,000. Simplify Asset Management Inc. boosted its holdings in shares of Masimo by 120.4% during the second quarter. Simplify Asset Management Inc. now owns 21,670 shares of the medical equipment provider’s stock worth $2,729,000 after purchasing an additional 11,838 shares during the period. State Board of Administration of Florida Retirement System grew its position in Masimo by 11.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 54,839 shares of the medical equipment provider’s stock valued at $8,053,000 after purchasing an additional 5,688 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Masimo by 32.1% in the 1st quarter. Advisors Asset Management Inc. now owns 9,009 shares of the medical equipment provider’s stock valued at $1,323,000 after buying an additional 2,187 shares during the period. Finally, Thrivent Financial for Lutherans boosted its stake in shares of Masimo by 42.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after buying an additional 360,497 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.